Izbicka E, Lawrence R, Davidson K, Rake J B, Von Hoff D D
Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX 78245, USA.
Invest New Drugs. 1998;16(3):221-5. doi: 10.1023/a:1006152100299.
Thioxanthones are aromatic hydrocarbons with cytotoxic activity against several tumor models. Potential mechanisms of action may include DNA intercalation, inhibition of nucleic acid biosynthesis, and topoisomerase inhibition, as well as formation of intracellular DNA single strand breaks. Such a broad spectrum of expected antitumor activity makes this class of compounds particularly interesting and worth pursuing in clinical studies. SW 33377 (Win 33377, SR 233377) was so promising in vitro that it was taken into Phase I clinical trials for further evaluation. The compound had undesirable cardiac effects, so new analogs were sought that would have similar antitumor effects without the undesirable side effects. In the present study, two new analogs SW 68210 (WIN 68210), and SW 71425 (WIN 71425) are compared to the antiproliferative action of SW 33377 against a variety of freshly explanted human tumor specimens using an in vitro soft agar cloning system. All compounds were more effective with continuous exposure than 1 hour exposure and a concentration-response effect was evident with all compounds. SW 68210 with continuous exposure showed similar activity to SW 33377 at all concentrations. SW 71425 with continuous exposure was less effective at the lower concentrations but was nearly as effective at 10 microg/ml as the other two compounds and was highly effective at 50 microg/ml. At the 10 microg/ml concentration all compounds were similarly effective against breast, colon, non-small cell lung, and ovarian tumors. The two new analogs, SW 68210 and SW 71425 have activity similar to SW 33377 and are both likely candidates for further development.
噻吨酮是一类芳香烃,对多种肿瘤模型具有细胞毒性活性。其潜在的作用机制可能包括DNA嵌入、抑制核酸生物合成、抑制拓扑异构酶,以及形成细胞内DNA单链断裂。如此广泛的预期抗肿瘤活性使得这类化合物特别有趣,值得在临床研究中进行探索。SW 33377(Win 33377,SR 233377)在体外表现出很大的潜力,因此进入了I期临床试验进行进一步评估。该化合物具有不良的心脏效应,因此人们寻求新的类似物,使其具有相似的抗肿瘤作用而没有不良副作用。在本研究中,使用体外软琼脂克隆系统,将两种新的类似物SW 68210(WIN 68210)和SW 71425(WIN 71425)与SW 33377对各种新鲜切除的人类肿瘤标本的抗增殖作用进行了比较。所有化合物持续暴露时比暴露1小时更有效,并且所有化合物都有明显的浓度-反应效应。持续暴露的SW 68210在所有浓度下都显示出与SW 33377相似的活性。持续暴露的SW 71425在较低浓度下效果较差,但在10微克/毫升时几乎与其他两种化合物一样有效,在50微克/毫升时非常有效。在10微克/毫升浓度下,所有化合物对乳腺癌、结肠癌、非小细胞肺癌和卵巢癌肿瘤的效果相似。两种新的类似物SW 68210和SW 71425具有与SW 33377相似的活性,都有可能是进一步开发的候选药物。